Suppr超能文献

低密度脂蛋白的逆向内吞作用。溶酶体抑制剂对培养的皮肤成纤维细胞中未降解的、成分改变的125I-低密度脂蛋白释放的影响。

Retroendocytosis of low density lipoprotein. Effect of lysosomal inhibitors on the release of undegraded 125I-low density lipoprotein of altered composition from skin fibroblasts in culture.

作者信息

Greenspan P, St Clair R W

出版信息

J Biol Chem. 1984 Feb 10;259(3):1703-13.

PMID:6693431
Abstract

Retroendocytosis of low density lipoprotein (LDL) is a newly identified pathway of cellular LDL processing in which LDL that has been internalized via LDL receptors is subsequently re-excreted from the cell and not degraded in the lysosomes. In the present study, we examined several characteristics of the retroendocytosis process as well as some of the physical characteristics of the retroendocytosed LDL. Monkey skin fibroblasts were pulse labeled with 125I-LDL for 4 h at 37 degrees C and were then washed extensively to remove both surface and LDL receptor-bound 125I-LDL. Retroendocytosis of LDL was determined by measuring the release of trichloroacetic acid-precipitable 125I-material during a subsequent 2-h chase period. In the presence of the lysosomotropic agents, chloroquine and methylamine, the absolute amount of LDL retroendocytosed was increased up to 3-fold. Without the lysosomotropic agents, less than 10% of the cell-associated 125I-LDL was lost by retroendocytosis in a 2-h chase period; this value increased to as much as 30% in the presence of the lysosomotropic agents. In the presence of lysosomotropic agents, the amount of LDL processed by retroendocytosis was approximately equivalent to the amount of LDL that was degraded. This enhancement of retroendocytosis was seen at 37 degrees C but not at 4 degrees C and was observed only when the lysosomotropic agents were present during the pulse period. Thus, the enhanced retroendocytosis was not a direct effect of the lysosomotropic agents but, instead, was probably secondary to the buildup of undegraded LDL within the cell. As a result, under certain conditions, retroendocytosis of LDL may be a quantitatively important alternate pathway for the cellular processing of LDL. In the absence of lysosomal inhibitors, up to one-third of the retroendocytosed material could have come from 125I-LDL that had not been removed from the cell surface prior to the chase period. In the presence of the lysosomotropic agents, however, less than 10% could have come from the cell surface. The enhancement of retroendocytosis by the lysosomotropic agents was not the result of cytotoxic effects of these agents since release of [3H]leucine-labeled cell proteins was altered only slightly. Thus, the bulk of the retroendocytosed LDL resulted from an active metabolic process for the efflux of LDL that had previously been internalized by the cell.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

低密度脂蛋白(LDL)的逆向内吞作用是一种新发现的细胞LDL处理途径,即通过LDL受体内化的LDL随后从细胞中重新排出,而不在溶酶体中降解。在本研究中,我们研究了逆向内吞过程的几个特征以及逆向内吞的LDL的一些物理特性。将猴皮肤成纤维细胞在37℃下用125I-LDL脉冲标记4小时,然后广泛洗涤以去除表面和与LDL受体结合的125I-LDL。通过在随后的2小时追踪期内测量三氯乙酸可沉淀的125I物质的释放来确定LDL的逆向内吞作用。在溶酶体促渗剂氯喹和甲胺存在下,逆向内吞的LDL绝对量增加高达3倍。在没有溶酶体促渗剂的情况下,在2小时追踪期内,通过逆向内吞作用丢失的细胞相关125I-LDL不到10%;在溶酶体促渗剂存在下,该值增加到高达30%。在溶酶体促渗剂存在下,通过逆向内吞作用处理的LDL量大约相当于被降解的LDL量。这种逆向内吞作用的增强在37℃时可见,但在4℃时不可见,并且仅在脉冲期存在溶酶体促渗剂时才观察到。因此,增强的逆向内吞作用不是溶酶体促渗剂的直接作用,而是可能继发于细胞内未降解LDL的积累。结果,在某些条件下,LDL的逆向内吞作用可能是细胞处理LDL的一个数量上重要的替代途径。在没有溶酶体抑制剂的情况下,高达三分之一的逆向内吞物质可能来自在追踪期之前未从细胞表面去除的125I-LDL。然而,在溶酶体促渗剂存在下,不到10%可能来自细胞表面。溶酶体促渗剂对逆向内吞作用的增强不是这些试剂细胞毒性作用的结果,因为[3H]亮氨酸标记的细胞蛋白的释放仅略有改变。因此,大部分逆向内吞的LDL是由细胞先前内化的LDL流出的活跃代谢过程产生的。(摘要截短至400字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验